Tags

Type your tag names separated by a space and hit enter

A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome.

Abstract

BACKGROUND

There is scarce data on the effects of magnesium-zinc-calcium-vitamin D co-supplementation on glycemic control and markers of cardio-metabolic risk among women with polycystic ovary syndrome (PCOS). The objective of this study was to assess the effects of magnesium-zinc-calcium-vitamin D co-supplementation on glycemic control and markers of cardio-metabolic risk in women with PCOS.

METHODS

Sixty PCOS women were randomized into two groups and treated with 100 mg of magnesium, 4 mg of zinc, 400 mg of calcium plus 200 IU of vitamin D supplements (n = 30) or placebo (n = 30) twice a day for 12 weeks. Glycemic control and markers of cardio-metabolic risk were assessed at baseline and at the end of trial.

RESULTS

After the 12-week intervention, compared with the placebo, magnesium-zinc-calcium-vitamin D co-supplementation supplementation resulted in significant reductions in serum insulin levels (-1.9 ± 4.6 vs. +0.4 ± 2.8 µIU/mL, P = 0.01), and homeostatic model of assessment for insulin resistance (-0.4 ± 1.0 vs. +0.1 ± 0.6, P = 0.02), as well as a significant increase in quantitative insulin sensitivity check index (+0.01 ± 0.02 vs. -0.0003 ± 0.01, P = 0.02). In addition, magnesium-zinc-calcium-vitamin D co-supplementation significantly decreased serum triglycerides (-26.5 ± 42.9 vs. +8.9 ± 17.9 mg/dL, P < 0.001), VLDL-cholesterol concentrations (-5.3 ± 8.6 vs. +1.8 ± 3.6 mg/dL, P < 0.001), total cholesterol (-4.2 ± 30.7 vs. +11.1 ± 28.4 mg/dL, P = 0.04) and total-/HDL-cholesterol ratio (-0.04 ± 0.6 vs. +0.3 ± 0.9, P = 0.04) compared with the placebo.

CONCLUSION

Overall, the results of this study demonstrated that magnesium-zinc-calcium-vitamin D co-supplementation for 12 weeks among patients with PCOS had beneficial effects on insulin metabolism and markers of cardio-metabolic risk.

Links

Authors+Show Affiliations

,

Endocrinology and Metabolism Research Center, Department of Gynecology and Obstetrics, School of Medicine, Arak University of Medical Sciences, Arak, Iran.

,

Endocrinology and Metabolism Research Center, Department of Gynecology and Obstetrics, School of Medicine, Arak University of Medical Sciences, Arak, Iran.

Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran.

Source

Archives of Iranian medicine 20:10 2017 Oct pg 640-645

MeSH

Adult
Biomarkers
Blood Glucose
Calcium
Cholesterol, HDL
Cholesterol, VLDL
Dietary Supplements
Double-Blind Method
Female
Humans
Insulin
Insulin Resistance
Magnesium
Polycystic Ovary Syndrome
Triglycerides
Vitamins
Young Adult
Zinc

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

29137465

Citation

Jamilian, Mehri, et al. "A Trial On the Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation On Glycemic Control and Markers of Cardio-Metabolic Risk in Women With Polycystic Ovary Syndrome." Archives of Iranian Medicine, vol. 20, no. 10, 2017, pp. 640-645.
Jamilian M, Maktabi M, Asemi Z. A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome. Arch Iran Med. 2017;20(10):640-645.
Jamilian, M., Maktabi, M., & Asemi, Z. (2017). A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome. Archives of Iranian Medicine, 20(10), pp. 640-645.
Jamilian M, Maktabi M, Asemi Z. A Trial On the Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation On Glycemic Control and Markers of Cardio-Metabolic Risk in Women With Polycystic Ovary Syndrome. Arch Iran Med. 2017;20(10):640-645. PubMed PMID: 29137465.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Trial on The Effects of Magnesium-Zinc-Calcium-Vitamin D Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome. AU - Jamilian,Mehri, AU - Maktabi,Maryam, AU - Asemi,Zatollah, PY - 2017/11/16/entrez PY - 2017/11/16/pubmed PY - 2018/7/4/medline SP - 640 EP - 645 JF - Archives of Iranian medicine JO - Arch Iran Med VL - 20 IS - 10 N2 - BACKGROUND: There is scarce data on the effects of magnesium-zinc-calcium-vitamin D co-supplementation on glycemic control and markers of cardio-metabolic risk among women with polycystic ovary syndrome (PCOS). The objective of this study was to assess the effects of magnesium-zinc-calcium-vitamin D co-supplementation on glycemic control and markers of cardio-metabolic risk in women with PCOS. METHODS: Sixty PCOS women were randomized into two groups and treated with 100 mg of magnesium, 4 mg of zinc, 400 mg of calcium plus 200 IU of vitamin D supplements (n = 30) or placebo (n = 30) twice a day for 12 weeks. Glycemic control and markers of cardio-metabolic risk were assessed at baseline and at the end of trial. RESULTS: After the 12-week intervention, compared with the placebo, magnesium-zinc-calcium-vitamin D co-supplementation supplementation resulted in significant reductions in serum insulin levels (-1.9 ± 4.6 vs. +0.4 ± 2.8 µIU/mL, P = 0.01), and homeostatic model of assessment for insulin resistance (-0.4 ± 1.0 vs. +0.1 ± 0.6, P = 0.02), as well as a significant increase in quantitative insulin sensitivity check index (+0.01 ± 0.02 vs. -0.0003 ± 0.01, P = 0.02). In addition, magnesium-zinc-calcium-vitamin D co-supplementation significantly decreased serum triglycerides (-26.5 ± 42.9 vs. +8.9 ± 17.9 mg/dL, P < 0.001), VLDL-cholesterol concentrations (-5.3 ± 8.6 vs. +1.8 ± 3.6 mg/dL, P < 0.001), total cholesterol (-4.2 ± 30.7 vs. +11.1 ± 28.4 mg/dL, P = 0.04) and total-/HDL-cholesterol ratio (-0.04 ± 0.6 vs. +0.3 ± 0.9, P = 0.04) compared with the placebo. CONCLUSION: Overall, the results of this study demonstrated that magnesium-zinc-calcium-vitamin D co-supplementation for 12 weeks among patients with PCOS had beneficial effects on insulin metabolism and markers of cardio-metabolic risk. SN - 1735-3947 UR - https://www.unboundmedicine.com/medline/citation/29137465/A_Trial_on_The_Effects_of_Magnesium_Zinc_Calcium_Vitamin_D_Co_Supplementation_on_Glycemic_Control_and_Markers_of_Cardio_Metabolic_Risk_in_Women_with_Polycystic_Ovary_Syndrome_ L2 - https://medlineplus.gov/polycysticovarysyndrome.html DB - PRIME DP - Unbound Medicine ER -